About: Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
Creator	Wang, Min Chen, Xiao Ding, Dan Chen, Fen Deng, Yihuan Du, Yimei Hu, Xiajun Liao, Yuhua Qiu, Zhihua Wang, Liangping Wang, Shijia Wu, Hailang Yan, Sen Yang, Shijun Yu, Xian Zhang, Hongrong Zhou, Yanzhao Zhou, Zihua
Source	PMC
abstract	ABSTRACT: Recently, our group has developed a therapeutic hypertensive vaccine against angiotensin (Ang) II type 1 receptor (AT1R) named ATRQβ-001. To explore its potential effectiveness on streptozotocin-induced diabetic nephropathy, male Sprague Dawley rats were randomly divided into two groups: a control and a diabetic model. After 1 week, the diabetic rats were divided into four subgroups (each with 15 rats) for 14-week treatments with saline, olmesartan, ATRQβ-001, and Qβ virus-like particle (VLP), respectively. In addition to lower blood pressure, ATRQβ-001 vaccination ameliorated biochemical parameter changes of renal dysfunction, mesangial expansion, and fibrosis through inhibiting oxidative stress, macrophage infiltration, and proinflammatory factor expression. Furthermore, ATRQβ-001 vaccination suppressed renal Ang II-AT1R activation and abrogated the downregulation of angiotensin-converting enzyme 2-Ang (1–7), similar to olmesartan treatment, while no obvious feedback activation of circulating or local renin-angiotensin system (RAS) was only observed in vaccine group. In rat mesangial cells, the anti-ATR-001 antibody inhibited high glucose-induced transforming growth factor-β1 (TGF)-β1/Smad3 signal pathway. Additionally, no significant immune-mediated damage was detected in vaccinated animals. In conclusion, the ATRQβ-001 vaccine ameliorated streptozotocin-induced diabetic renal injury via modulating two RAS axes and inhibiting TGF-β1/Smad3 signal pathway, providing a novel, safe, and promising method to treat diabetic nephropathy. KEY MESSAGES: Overactivation of RAS plays a crucial role in the development of the DN. Our aim was to verify the effectiveness of ATRQβ-001 vaccine in STZ-induced DN. The ATRQβ-001 modulated two RAS axes and inhibited TGF-β1/Smad3 signal pathway. The vaccine therapy may provide a novel, safe, and promising method to treat DN. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00109-015-1343-6) contains supplementary material, which is available to authorized users.
has issue date	2015-09-26(xsd:dateTime)
bibo:doi	10.1007/s00109-015-1343-6
bibo:pmid	26407577
has license	cc-by
sha1sum (hex)	710127845c3bf0670bd685616f56b3d18e53ebce
schema:url	https://doi.org/10.1007/s00109-015-1343-6
resource representing a document's title	Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
has PubMed Central identifier	PMC4762923
has PubMed identifier	26407577
schema:publication	J Mol Med (Berl)
resource representing a document's body	covid:710127845c3bf0670bd685616f56b3d18e53ebce#body_text
is schema:about of	named entity 'diabetic nephropathy' named entity 'randomly' named entity 'angiotensin' named entity 'diabetic nephropathy' named entity 'streptozotocin' named entity 'Vaccination' named entity 'Blood samples' named entity 'Animal Models' named entity 'glomeruli' named entity 'RAS' named entity 'RAS' named entity 'Ang II' named entity 'fibrosis' named entity 'Monoclonal antibodies' named entity 'AT1R' named entity 'diabetic' named entity 'ECM' named entity 'significant difference' named entity 'ARBs' named entity 'podocytes' named entity 'cytotoxicity' named entity 'hematoxylin-eosin' named entity 'olmesartan' named entity 'excretion' named entity 'sodium citrate' named entity 'losartan' named entity 'VLP' named entity 'kidney cortex' named entity 'Diabetic nephropathy' named entity 'nephropathy' named entity 'RAS' named entity 'animal research' named entity 'olmesartan' named entity 'TGF-β1' named entity 'vaccination' named entity 'diabetes' named entity 'TGF-β1' named entity 'PAS' named entity 'pmol' named entity 'diabetic' named entity 'receptor' named entity 'AT1R' named entity 'inflammation' named entity 'TGF-β1' named entity 'Western blot' named entity 'metabolic' named entity 'subcutaneous injection' named entity 'AT1R' named entity 'antibody' named entity 'signal transduction' named entity 'histopathology' named entity 'podocyte' named entity 'long-term' named entity 'proinflammatory' named entity 'creatinine' named entity 'significant difference' named entity 'antibody' named entity 'fibrosis' named entity 'olmesartan' named entity 'RMCs' named entity 'dimercaprol' named entity 'vaccine' named entity 'vaccination' named entity 'China'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software